Opioid Analgesia and Opioid-Induced Adverse Effects: A Review

IASP (2021, October 26). Pain, IASP Terminology. International Association for the Study of Pain (IASP). Available online: https://www.iasp-pain.org/resources/terminology/#pain.

Woolf, 1998, Towards a mechanism-based classification of pain?, Pain, 77, 227, 10.1016/S0304-3959(98)00099-2

Woolf, 1999, Neuropathic pain: Aetiology, symptoms, mechanisms, and management, Lancet, 353, 1959, 10.1016/S0140-6736(99)01307-0

Fitzcharles, 2021, Nociplastic pain: Towards an understanding of prevalent pain conditions, Lancet, 397, 2098, 10.1016/S0140-6736(21)00392-5

Nijs, J., Lahousse, A., Kapreli, E., Bilika, P., Saraçoğlu, I., Malfliet, A., Coppieters, I., De Baets, L., Leysen, L., and Roose, E. (2021). Nociplastic pain criteria or recognition of central sensitization? Pain phenotyping in the past, present and future. J. Clin. Med., 10.

IASP (2021, August 25). Central Sensitization, IASP Terminology. Available online: https://www.iasp-pain.org/resources/terminology/?navItemNumber=576#Centralsensitization.

Cai, 2012, Opioid system and Alzheimer’s disease, Neuromol. Med., 14, 91, 10.1007/s12017-012-8180-3

Melzack, 1999, From the gate to the neuromatrix, Pain, 82, S121, 10.1016/S0304-3959(99)00145-1

Holden, 2005, The endogenous opioid system and clinical pain management, AACN Clin. Issues Adv. Pr. Acute Crit. Care, 16, 291

Becker, 2009, Reward processing by the opioid system in the brain, Physiol. Rev., 89, 1379, 10.1152/physrev.00005.2009

Beckett, 2011, Synthetic analgesics: Stereochemical considerations, J. Pharm. Pharmacol., 6, 986, 10.1111/j.2042-7158.1954.tb11033.x

Martin, 1976, The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog, J. Pharmacol. Exp. Ther., 197, 517

Borsodi, A., Bruchas, M., Caló, G., Chavkin, C., Christie, M.J., Civelli, O., Connor, M., Cox, B.M., Devi, L.A., and Evans, C. (2021, October 26). Opioid Receptors, Introduction. IUPHAR/BPS Guide to PHARMACOLOGY. Available online: http://www.guidetoimmunopharmacology.org/GRAC/FamilyIntroductionForward?familyId=50.

Alexander, 2013, The concise guide to PHARMACOLOGY 2013/14: G Protein-Coupled receptors, Br. J. Pharmacol., 170, 1459, 10.1111/bph.12445

Waldhoer, 2004, Opioid receptors, Annu. Rev. Biochem., 73, 953, 10.1146/annurev.biochem.73.011303.073940

Chen, 1993, Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors, Biochem. J., 295, 625, 10.1042/bj2950625

Mollereau, 1994, ORL1, a novel member of the opioid receptor family, FEBS Lett., 341, 33, 10.1016/0014-5793(94)80235-1

Granier, 2012, Structure of the δ-opioid receptor bound to naltrindole, Nat. Cell Biol., 485, 400

Filizola, 2012, How opioid drugs bind to receptors, Nat. Cell Biol., 485, 314

Manglik, 2012, Crystal structure of the µ-opioid receptor bound to a morphinan antagonist, Nat. Cell Biol., 485, 321

Thompson, 2012, Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic, Nat. Cell Biol., 485, 395

Wu, 2012, Structure of the human κ-opioid receptor in complex with JDTic, Nat. Cell Biol., 485, 327

Matthes, 1996, Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene, Nat. Cell Biol., 383, 819

Kieffer, 1999, Opioids: First lessons from knockout mice, Trends Pharmacol. Sci., 20, 19, 10.1016/S0165-6147(98)01279-6

Sora, 1997, Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia, Proc. Natl. Acad. Sci. USA, 94, 1544, 10.1073/pnas.94.4.1544

Corbett, 2006, 75 years of opioid research: The exciting but vain quest for the Holy Grail, Br. J. Pharmacol., 147, S153, 10.1038/sj.bjp.0706435

Williams, 2013, Regulation of µ-opioid receptors: Desensitization, phosphorylation, internalization, and tolerance, Pharmacol. Rev., 65, 223, 10.1124/pr.112.005942

Machelska, 2018, Advances in achieving opioid analgesia without side effects, Front. Pharmacol., 9, 1388, 10.3389/fphar.2018.01388

Darcq, 2018, Opioid receptors: Drivers to addiction?, Nat. Rev. Neurosci., 19, 499, 10.1038/s41583-018-0028-x

Romberg, 2003, Comparison of morphine-6-glucuronide and morphine on respiratory depressant and antinociceptive responses in wild type and mu-opioid receptor deficient mice, Br. J. Anaesth., 91, 862, 10.1093/bja/aeg279

Mori, 2013, Mechanisms that underlie μ-opioid receptor agonist–induced constipation: Differential involvement of μ-opioid receptor sites and responsible regions, J. Pharmacol. Exp. Ther., 347, 91, 10.1124/jpet.113.204313

Daniels, 2005, Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series, Proc. Natl. Acad. Sci. USA, 102, 19208, 10.1073/pnas.0506627102

Pradhan, 2010, Ligand-directed trafficking of the-opioid receptor in vivo: Two paths toward analgesic tolerance, J. Neurosci., 30, 16459, 10.1523/JNEUROSCI.3748-10.2010

Fraser, 2000, Antihyperalgesic effects of δ opioid agonists in a rat model of chronic inflammation, Br. J. Pharmacol., 129, 1668, 10.1038/sj.bjp.0703248

Cahill, 2003, Up-regulation and trafficking of delta opioid receptor in a model of chronic inflammation: Implications for pain control, Pain, 101, 199, 10.1016/S0304-3959(02)00333-0

Nozaki, 2011, Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia, Pain, 152, 1238, 10.1016/j.pain.2010.12.031

Kabli, 2007, Anti-Allodynic effects of peripheral delta opioid receptors in neuropathic pain, Pain, 127, 84, 10.1016/j.pain.2006.08.003

Smith, 2006, Cancer-related bone pain is attenuated by a systemically available δ-opioid receptor agonist, Pain, 122, 174, 10.1016/j.pain.2006.01.032

Vanderah, 2010, Delta and kappa opioid receptors as suitable drug targets for pain, Clin. J. Pain, 26, S10, 10.1097/AJP.0b013e3181c49e3a

Gendron, 2015, Recent advances on the δ opioid receptor: From trafficking to function, Br. J. Pharmacol., 172, 403, 10.1111/bph.12706

Dykstra, 1993, A novel delta opioid agonist, BW373U86, in squirrel monkeys responding under a schedule of shock titration, J. Pharmacol. Exp. Ther., 267, 875

Negus, 1994, Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys, J. Pharmacol. Exp. Ther., 270, 1025

Negus, 1998, Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys, J. Pharmacol. Exp. Ther., 286, 362

Nozaki, 2012, δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: Analgesia, locomotion, and receptor internalization, J. Pharmacol. Exp. Ther., 342, 799, 10.1124/jpet.111.188987

Broom, 2002, Comparison of receptor mechanisms and efficacy requirements for δ-agonist-induced convulsive activity and antinociception in mice, J. Pharmacol. Exp. Ther., 303, 723, 10.1124/jpet.102.036525

Eisenach, 2003, Analgesia from a peripherally active κ-opioid receptor agonist in patients with chronic pancreatitis, Pain, 101, 89, 10.1016/S0304-3959(02)00259-2

Riviere, 2004, Peripheral kappa-opioid agonists for visceral pain, Br. J. Pharmacol., 141, 1331, 10.1038/sj.bjp.0705763

Moon, 2016, The contribution of activated peripheral kappa opioid receptors (kORs) in the inflamed knee joint to anti-nociception, Brain Res., 1648, 11, 10.1016/j.brainres.2016.06.048

Spetea, 2001, Contralateral but not systemic administration of the κ-opioid agonist U-50,488H induces anti-nociception in acute hindpaw inflammation in rats, Br. J. Pharmacol., 132, 252, 10.1038/sj.bjp.0703782

Keita, 1995, Antinociceptive effect of a kappa-opioid receptor agonist that minimally crosses the blood-brain barrier (ICI 204448) in a rat model of mononeuropathy, Eur. J. Pharmacol., 277, 275, 10.1016/0014-2999(95)00122-2

Spetea, 2004, Contralateral, ipsilateral and bilateral treatments with the κ-opioid receptor agonist U-50,488H in mononeuropathic rats, Eur. J. Pharmacol., 494, 139, 10.1016/j.ejphar.2004.04.043

Dykstra, 1987, Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects, J. Pharmacol. Exp. Ther., 242, 413

Butelman, 1999, Effects of E-2078, a stable dynorphin A(1-8) analog, on sedation and serum prolactin levels in rhesus monkeys, Psychopharmacology, 147, 73, 10.1007/s002130051144

Ko, 1999, Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys, J. Pharmacol. Exp. Ther., 291, 1113

Peng, 2007, Kappa receptor bivalent ligands, Curr. Top. Med. Chem., 7, 363, 10.2174/156802607779941251

Rizzi, 2010, UFP-112 a potent and long-lasting agonist selective for the nociceptin/orphanin FQ receptor, CNS Neurosci. Ther., 17, 178

Rizzi, 2007, In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor, Peptides, 28, 1240, 10.1016/j.peptides.2007.04.020

Hu, 2010, Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112, Pain, 148, 107, 10.1016/j.pain.2009.10.026

Ko, 2009, Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys, Neuropsychopharmacology, 34, 2088, 10.1038/npp.2009.33

Varty, 2008, The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510), J. Pharmacol. Exp. Ther., 326, 672, 10.1124/jpet.108.136937

Lin, 2012, The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability, ACS Chem. Neurosci., 4, 214, 10.1021/cn300124f

Dautzenberg, 2001, Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: Rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo, J. Pharmacol. Exp. Ther., 298, 812

Reiss, 2008, Effects of nociceptin/orphanin FQ receptor (NOP) agonist, Ro64-6198, on reactivity to acute pain in mice: Comparison to morphine, Eur. J. Pharmacol., 579, 141, 10.1016/j.ejphar.2007.10.031

Obara, 2005, Spinal and local peripheral antiallodynic activity of Ro64-6198 in neuropathic pain in the rat, Pain, 116, 17, 10.1016/j.pain.2005.03.012

Pathan, 2012, Basic opioid pharmacology: An update, Br. J. Pain, 6, 11, 10.1177/2049463712438493

Schuller, 1999, Retention of heroin and morphine–6β–glucuronide analgesia in a new line of mice lacking exon 1 of MOR–1, Nat. Neurosci., 2, 151, 10.1038/5706

Loh, 1998, mu Opioid receptor knockout in mice: Effects on ligand-induced analgesia and morphine lethality, Brain Res. Mol. Brain Res., 54, 321, 10.1016/S0169-328X(97)00353-7

Zhu, 1999, Retention of supraspinal delta-like analgesia and loss of morphine tolerance in δ opioid receptor knockout mice, Neuron, 24, 243, 10.1016/S0896-6273(00)80836-3

Simonin, 1998, Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal, EMBO J., 17, 886, 10.1093/emboj/17.4.886

Matthes, 1998, Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor, J. Neurosci., 18, 7285, 10.1523/JNEUROSCI.18-18-07285.1998

Hosohata, 2000, Delta-opioid receptor agonists produce antinociception and [35S]GTPgammaS binding in mu receptor knockout mice, Eur. J. Pharmacol., 388, 241, 10.1016/S0014-2999(99)00897-3

Van Miert, A.S.J.P.A.M., Bogaert, M.G., and Debackere, M. (1986). Opioid peptides and their receptors. Comparative Veterinary Pharmacology, Toxicology and Theraphy, Springer.

Ahmed, 2006, Opioid peptides and receptors in joint tissues: Study in the rat, J. Orthop. Res., 24, 1193, 10.1002/jor.20132

Callahan, 1987, Opiates, opioid peptides, and their receptors, J. Cardiothorac. Anesth., 1, 569, 10.1016/0888-6296(87)90046-9

Chaturvedi, 2003, Opioid peptides, opioid receptors and mechanism of down regulation, Indian J. Exp. Boil., 41, 5

Snyder, 1979, Opiate receptors and opioid peptides, Annu. Rev. Neurosci., 2, 35, 10.1146/annurev.ne.02.030179.000343

Marino, 2015, Diagnostic and short-term prognostic utility of plasma pro-enkephalin (pro-ENK) for acute kidney injury in patients admitted with sepsis in the emergency department, J. Nephrol., 28, 717, 10.1007/s40620-014-0163-z

Roberts, 2007, Tracking the evolution of the proenkephalin gene in tetrapods, Gen. Comp. Endocrinol., 153, 189, 10.1016/j.ygcen.2007.02.023

Rodriguez, 2003, Characterization of zebrafish proenkephalin reveals novel opioid sequences, Brain Res. Mol. Brain Res., 114, 31, 10.1016/S0169-328X(03)00126-8

Merg, 2006, Big dynorphin as a putative endogenous ligand for the kappa-opioid receptor, J. Neurochem., 97, 292, 10.1111/j.1471-4159.2006.03732.x

Gein, 2014, Dynorphins in regulation of immune system functions, Biochemistry, 79, 397

Diamant, 1989, Beta-endorphin and related peptides suppress phorbol myristate acetate-induced respiratory burst in human polymorphonuclear leukocytes, Life Sci., 45, 1537, 10.1016/0024-3205(89)90419-0

Lolait, 1986, Pro-opiomelanocortin messenger ribonucleic acid and posttranslational processing of beta endorphin in spleen macrophages, J. Clin. Investig., 77, 1776, 10.1172/JCI112501

Bodnar, 2013, Endogenous opiates and behavior: 2012, Peptides, 50, 55, 10.1016/j.peptides.2013.10.001

Fine, P.G., and Portenoy, R.K. (2004). A Clinical Guide to Opioid Analgesia, The McGraw-Hill Companies.

(2017, October 22). AMH. Analgesics (Ch 3). In Australian Medicines Handbook (AMH). Available online: https://amhonline.amh.net.au/chapters/chap-03?menu=vertical.

Pasternak, 2014, Opiate pharmacology and relief of pain, J. Clin. Oncol., 32, 1655, 10.1200/JCO.2013.53.1079

Pena, D.A., Duarte, M.L., Pramio, D.T., Devi, L.A., and Schechtman, D. (2018). Exploring morphine-triggered PKC-targets and their interaction with signaling pathways leading to pain via TrkA. Proteomes, 6.

Pasternak, G.W. (2011). Opioid receptor signal transduction mechanism. The Opiate Receptors, Humana Press. [2nd ed.].

Witkowski, 2006, Opioid μ receptor activation inhibits sodium currents in prefrontal cortical neurons via a protein kinase A- and C-dependent mechanism, Brain Res., 1094, 92, 10.1016/j.brainres.2006.03.119

Vega, 2014, Activation of μ-opioid receptors inhibits calcium-currents in the vestibular afferent neurons of the rat through a cAMP dependent mechanism, Front. Cell. Neurosci., 8, 90

Altarejos, 2011, CREB and the CRTC co-activators: Sensors for hormonal and metabolic signals, Nat. Rev. Mol. Cell Biol., 12, 141, 10.1038/nrm3072

Lei, 2018, L-3-n-Butylphthalide regulates proliferation, migration, and differentiation of neural stem cell in vitro and promotes neurogenesis in APP/PS1 mouse model by regulating BDNF/TrkB/CREB/Akt pathway, Neurotox. Res., 34, 477, 10.1007/s12640-018-9905-3

Xia, 2018, Targeting CREB Pathway Suppresses Small Cell Lung Cancer, Mol. Cancer Res., 16, 825, 10.1158/1541-7786.MCR-17-0576

Smith, T.H., Grider, J.R., Dewey, W.L., and Akbarali, H.I. (2012). Morphine decreases enteric neuron excitability via inhibition of sodium channels. PLoS ONE, 7.

Shirahama, 2012, Inhibition of Ca2+/Calmodulin-Dependent protein kinase II reverses oxaliplatin-induced mechanical allodynia in rats, Mol. Pain, 8, 26, 10.1186/1744-8069-8-26

Hudson, 2018, Dual Role of CREB in the regulation of VSMC Proliferation: Mode of activation determines pro-or anti-mitogenic function, Sci. Rep., 8, 4904, 10.1038/s41598-018-23199-4

Chen, 2008, The other side of the opioid story: Modulation of cell growth and survival signaling, Curr. Med. Chem., 15, 772, 10.2174/092986708783955518

Knapp, C.M. (2002). Opiates. Encyclopedia of the Human Brain, Academic Press.

Winters, 2017, Endogenous opioids regulate moment-to-moment neuronal communication and excitability, Nat. Commun., 8, 14611, 10.1038/ncomms14611

Ghelardini, 2015, The pharmacological basis of opioids, Clin. Cases Miner. Bone Metab., 12, 219

Hashimoto, 2009, μ-Opioid receptor-independent fashion of the suppression of sodium currents by μ-opioid analgesics in thalamic neurons, Neurosci. Lett., 453, 62, 10.1016/j.neulet.2009.01.066

Thompson, 2015, Biased agonism of endogenous opioid peptides at the μ-Opioid receptor, Mol. Pharmacol., 88, 335, 10.1124/mol.115.098848

Wisler, 2014, Recent developments in biased agonism, Curr. Opin. Cell Biol., 27, 18, 10.1016/j.ceb.2013.10.008

Kenakin, 2009, Biased agonism, F1000 Biol. Rep., 1, 87, 10.3410/B1-87

Kenakin, 2012, A simple method for quantifying functional selectivity and agonist bias, ACS Chem. Neurosci., 3, 193, 10.1021/cn200111m

Bruchas, 2011, Molecular mechanisms of opioid receptor-dependent signaling and behavior, Anesthesiology, 115, 1363, 10.1097/ALN.0b013e318238bba6

Molinari, 2010, Morphine-like opiates selectively antagonize receptor-arrestin interactions, J. Biol. Chem., 285, 12522, 10.1074/jbc.M109.059410

Bohn, 1999, Enhanced morphine analgesia in mice lacking beta-arrestin 2, Science, 286, 2495, 10.1126/science.286.5449.2495

Soergel, 2014, Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers, Pain, 155, 1829, 10.1016/j.pain.2014.06.011

DeWire, 2013, A G Protein-Biased Ligand at the μ-Opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine, J. Pharmacol. Exp. Ther., 344, 708, 10.1124/jpet.112.201616

Raehal, 2005, Morphine Side Effects in β-Arrestin 2 Knockout Mice, J. Pharmacol. Exp. Ther., 314, 1195, 10.1124/jpet.105.087254

Groer, 2007, An opioid agonist that does not induce μ-Opioid receptor—arrestin interactions or receptor internalization, Mol. Pharmacol., 71, 549, 10.1124/mol.106.028258

Maguma, 2012, Differences in the characteristics of tolerance to μ-opioid receptor agonists in the colon from wild type and β-arrestin2 knockout mice, Eur. J. Pharmacol., 685, 133, 10.1016/j.ejphar.2012.04.001

Spetea, 2017, Selective κ receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice, Br. J. Pharmacol., 174, 2444, 10.1111/bph.13854

Morgenweck, 2015, Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus, Neuropharmacology, 99, 600, 10.1016/j.neuropharm.2015.08.027

Jin, Z., Zhu, M., Gupta, A., Page, C., Gan, T.J., and Bergese, S.D. (2021). Evaluating oliceridine as a treatment option for moderate to severe acute post-operative pain in adults. Expert Opin. Pharmacother., 1–9.

Hammer, G.B., Khanna, A.K., Michalsky, C., Wase, L., Demitrack, M.A., Little, R., Fossler, M.J., and Ayad, S. (2021). Oliceridine exhibits improved tolerability compared to morphine at equianalgesic conditions: Exploratory analysis from two phase 3 randomized placebo and active controlled trials. Pain Ther., 1–11.

Devereaux, 2018, DARK classics in chemical neuroscience: Morphine, ACS Chem. Neurosci., 9, 2395, 10.1021/acschemneuro.8b00150

(2020, December 29). TG. Principles of Nonsteroidal Anti-Inflammatory Drug Use for Musculoskeletal Conditions in Adults. In eTG Complete Melbourne: Therapeutic Guidelines Limited. Available online: https://tgldcdp.tg.org.au/index.

CDC (2020, December 29). Prescription Opioids: Side Effects. Centers for Disease Control and Prevention, Available online: https://www.cdc.gov/drugoverdose/opioids/prescribed.html.

WHO (2021, October 26). Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. World Health Organization, Geneva. Available online: http://apps.who.int/iris/bitstream/10665/43948/1/9789241547543_eng.pdf.

Collin, 1993, Is disease progression the major factor in morphine ‘tolerance’ in cancer pain treatment?, Pain, 55, 319, 10.1016/0304-3959(93)90007-C

Freye, 2007, Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec®) in chronic pain patients, Pain Pract., 7, 123, 10.1111/j.1533-2500.2007.00119.x

Rhondali, 2013, Methadone rotation for cancer patients with refractory pain in a palliative care unit: An observational study, J. Palliat. Med., 16, 1382, 10.1089/jpm.2013.0222

Leppert, 2015, Long-term administration of high doses of transdermal buprenorphine in cancer patients with severe neuropathic pain, OncoTargets Ther., 8, 3621, 10.2147/OTT.S91347

Sutou, 2015, Fentanyl Tolerance in the Treatment of Cancer Pain: A Case of Successful Opioid Switching from Fentanyl to Oxycodone at a Reduced Equivalent Dose, J. Pain Palliat. Care Pharmacother., 29, 161, 10.3109/15360288.2015.1035832

Shinde, 2014, Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: Does this improve pain control and reduce opioid requirements?, Support. Care Cancer, 23, 695, 10.1007/s00520-014-2415-9

Raptis, 2013, Pregabalin Vs. Opioids for the treatment of neuropathic cancer pain: A prospective, head-to-head, randomized, open-label study, Pain Pract., 14, 32, 10.1111/papr.12045

Abdelhamid, 1991, Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice, J. Pharmacol. Exp. Ther., 258, 299

Fundytus, 1995, Attenuation of morphine tolerance and dependence with the highly selective delta-opioid receptor antagonist TIPP[psi], Eur. J. Pharmacol., 286, 105, 10.1016/0014-2999(95)00554-X

Hepburn, 1997, Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats, J. Pharmacol. Exp. Ther., 281, 1350

Roy, 2005, In vivo activation of a mutant-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: Role of-Receptor activation and-receptor blockade in morphine tolerance, J. Neurosci., 25, 3229, 10.1523/JNEUROSCI.0332-05.2005

Imam, 2018, Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression, Neuropharmacology, 131, 238, 10.1016/j.neuropharm.2017.12.032

Bie, 2007, Trafficking of central opioid receptors and descending pain inhibition, Mol. Pain, 3, 37, 10.1186/1744-8069-3-37

Bs, 2010, How to design an opioid drug that causes reduced tolerance and dependence, Ann. Neurol., 67, 559, 10.1002/ana.22002

Viet, 2017, OPRM1 methylation contributes to opioid tolerance in cancer patients, J. Pain, 18, 1046, 10.1016/j.jpain.2017.04.001

Groer, 2011, Agonist-directed Interactions with Specific β-Arrestins Determine μ-Opioid Receptor Trafficking, Ubiquitination, and Dephosphorylation, J. Biol. Chem., 286, 31731, 10.1074/jbc.M111.248310

Arttamangkul, 2018, Cellular tolerance at the µ-opioid receptor is phosphorylation dependent, eLife, 7, e34989, 10.7554/eLife.34989

Martini, 2007, The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence, Curr. Opin. Neurobiol., 17, 556, 10.1016/j.conb.2007.10.004

Bourova, 2010, Long-term adaptation to high doses of morphine causes desensitization of mu-OR- and delta-OR-stimulated G-protein response in forebrain cortex but does not decrease the amount of G-protein alpha subunits, Med. Sci. Monit., 16, 260

Gupta, 2010, Increased abundance of opioid receptor heteromers following chronic morphine administration, Sci. Signal., 3, ra54, 10.1126/scisignal.2000807

Leah, 2015, Chronic morphine reduces surface expression of δ-Opioid receptors in subregions of rostral striatum, Neurochem. Res., 41, 500, 10.1007/s11064-015-1638-6

Paul, A., Gueven, N., and Dietis, N. (2021). Profiling the effects of repetitive morphine administration on motor behavior in rats. Molecules, 26.

Paul, 2017, Morphine dosing strategy plays a key role in the generation and duration of the produced antinociceptive tolerance, Neuropharmacology, 121, 158, 10.1016/j.neuropharm.2017.04.034

McQuay, 1987, Central analgesics, Acta Neurochir. Suppl., 38, 41, 10.1007/978-3-7091-6975-9_7

Gozariu, 2001, Animal models of nociception, Pharmacol. Rev., 53, 597

1998, Aspects on Tail-Flick, Hot-Plate and electrical stimulation tests for morphine antinociception, Pharmacol. Toxicol., 83, 252, 10.1111/j.1600-0773.1998.tb01478.x

Labianca, 2012, Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain, Clin. Drug Investig., 32, 53, 10.2165/11630080-000000000-00000

Juurlink, 2012, Dependence and addiction during chronic opioid therapy, J. Med. Toxicol., 8, 393, 10.1007/s13181-012-0269-4

Ballantyne, 2007, Opioid dependence and addiction during opioid treatment of chronic pain, Pain, 129, 235, 10.1016/j.pain.2007.03.028

Nestler, 1997, Molecular and Cellular Basis of Addiction, Science, 278, 58, 10.1126/science.278.5335.58

Mai, J.K., and Paxinos, G. (2012). Chapter 12-Locus coeruleus. The Human Nervous System, Academic Press. [3rd ed.].

Kosten, 2002, The neurobiology of opioid dependence: Implications for treatment, Sci. Pract. Perspect., 1, 13, 10.1151/spp021113

Listos, J., Łupina, M., Talarek, S., Mazur, A., Orzelska-Górka, J., and Kotlińska, J. (2019). The mechanisms involved in morphine addiction: An overview. Int. J. Mol. Sci., 20.

Dowell, 2016, CDC Guideline for prescribing opioids for chronic pain—United States, 2016, JAMA, 315, 1624, 10.1001/jama.2016.1464

(PHE) Public Health England, Faculty of Medicine of the Royal College of Anaesthetists, Royal College of General Practitioners, and The British Pain Society (2016, September 24). Managing Persistent Pain in Secure Settings, Available online: http://www.nta.nhs.uk/uploads/persistentpain.pdf.

NOUGG (2016, September 24). Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain. Canada. National Opioid Use Guideline Group (NOUGG). Available online: http://nationalpaincentre.mcmaster.ca/opioid/.

American Society of Anesthesiologists Task Force on Chronic Pain Management (2010). American Society of Regional Anesthesia and Pain Medicine Practice Guidelines for Chronic Pain Management. Anesthesiology, 112, 810–833.

Trescot, 2008, Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians’ (ASIPP) Guidelines, Pain Physician, 11, S5

Kirpalani, 2015, How to maximize patient safety when prescribing opioids, PM&R, 7, S225, 10.1016/j.pmrj.2015.08.016

Stein, 2010, Opioid use in chronic noncancer pain: Guidelines revisited, Curr. Opin. Anaesthesiol., 23, 598, 10.1097/ACO.0b013e32833c57a8

Streicher, 2017, Peripherally acting μ-Opioid receptor antagonists for the treatment of opioid-related side effects: Mechanism of action and clinical implications, J. Pharm. Pr., 31, 658, 10.1177/0897190017732263

Camilleri, 2011, Opioid-Induced constipation: Challenges and therapeutic opportunities, Am. J. Gastroenterol., 106, 835, 10.1038/ajg.2011.30

Kon, 2015, Morphine-Induced constipation develops with increased aquaporin-3 expression in the colon via increased serotonin secretion, Toxicol. Sci., 145, 337, 10.1093/toxsci/kfv055

Akbarali, 2014, Site and mechanism of morphine tolerance in the gastrointestinal tract, Neurogastroenterol. Motil., 26, 1361, 10.1111/nmo.12443

Swegle, 2006, Management of common opioid-induced adverse effects, Am. Fam. Physician, 74, 1347

Cherny, 2001, For the expert working group of the european association of palliative care network strategies to manage the adverse effects of oral morphine: An evidence-based report, J. Clin. Oncol., 19, 2542, 10.1200/JCO.2001.19.9.2542

Prichard, 2016, Management of opioid-induced constipation, Br. J. Nurs., 25, S4, 10.12968/bjon.2016.25.10.S4

Meissner, 2000, Oral naloxone reverses opioid-associated constipation, Pain, 84, 105, 10.1016/S0304-3959(99)00185-2

Shimoyama, 2013, Treatment of constipation in chronic pain patients, Masui. Jpn. J. Anesthesiol., 62, 822

Burness, 2014, Oxycodone/naloxone prolonged-release: A review of its use in the management of chronic pain while counteracting opioid-induced constipation, Drugs, 74, 353, 10.1007/s40265-014-0177-9

Moore, 2005, Prevalence of opioid adverse events in chronic non-malignant pain: Systematic review of randomised trials of oral opioids, Arthritis Res., 7, R1046, 10.1186/ar1782

Watcha, 1992, Postoperative nausea and vomiting. Its etiology, treatment, and prevention, Anesthesiology, 77, 162, 10.1097/00000542-199207000-00023

Lehnen, N., Heuser, F., Saglam, M., Schulz, C.M., Wagner, K.J., Taki, M., Kochs, E.F., Jahn, K., Brandt, T., and Glasauer, S. (2015). Opioid-inducednausea involves a vestibular problem preventable by head-rest. PLoS ONE, 10.

Rojas, 2015, Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron), Cancer Treat. Rev., 41, 904, 10.1016/j.ctrv.2015.09.005

Rojas, 2014, Molecular mechanisms of 5-HT3 and NK1 receptor antagonists in prevention of emesis, Eur. J. Pharmacol., 722, 26, 10.1016/j.ejphar.2013.08.049

Koju, R.B., Gurung, B.S., and Dongol, Y. (2015). Prophylactic administration of ondansetron in prevention of intrathecal morphine-induced pruritus and post-operative nausea and vomiting in patients undergoing caesarean section. BMC Anesthesiol., 15.

Ashby, 1999, Opioid substitution to reduce adverse effects in cancer pain management, Med. J. Aust., 170, 68, 10.5694/j.1326-5377.1999.tb126885.x

Bruera, 1995, Opioid rotation for toxicity reduction in terminal cancer patients, J. Pain Symptom Manag., 10, 378, 10.1016/0885-3924(95)90924-C

Sultan, 2011, Neuraxial morphine and respiratory depression, Drugs, 71, 1807, 10.2165/11596250-000000000-00000

Kuo, 2014, In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: No two opioids have the same profile, Br. J. Pharmacol., 172, 532, 10.1111/bph.12696

Boom, 2012, Non-analgesic effects of opioids: Opioid-induced respiratory depression, Curr. Pharm. Des., 18, 5994, 10.2174/138161212803582469

Kamei, 2011, Effect of chronic pain on morphine-induced respiratory depression in mice, Neuroscience, 174, 224, 10.1016/j.neuroscience.2010.11.012

Hill, 2020, Fentanyl depression of respiration: Comparison with heroin and morphine, Br. J. Pharmacol., 177, 254, 10.1111/bph.14860

Manzke, 2003, 5-HT 4(a) Receptors avert opioid-induced breathing depression without loss of analgesia, Science, 301, 226, 10.1126/science.1084674

Pattinson, 2008, Opioids and the control of respiration, Br. J. Anaesth., 100, 747, 10.1093/bja/aen094

Manzke, 2011, Die von serotoninrezeptor 1A modulierte dephosphorylierung des glyzinrezeptors α3, Der. Schmerz, 25, 272, 10.1007/s00482-011-1044-1

Dunn, 2000, Finding an optimal dose: Considerations in accurate opioid dispensing, Vet. Hum. Toxicol., 42, 36

Lewanowitsch, 2002, Naloxone methiodide reverses opioid-induced respiratory depression and analgesia without withdrawal, Eur. J. Pharmacol., 445, 61, 10.1016/S0014-2999(02)01715-6

Droney, 2013, Analgesia and central side-effects: Two separate dimensions of morphine response, Br. J. Clin. Pharmacol., 75, 1340, 10.1111/bcp.12008

Babbini, 1972, Time-dose relationships for locomotor activity effects of morphine after acute or repeated treatment, Br. J. Pharmacol., 46, 213, 10.1111/j.1476-5381.1972.tb06866.x

Hollais, 2014, Effects of acute and long-term typical or atypical neuroleptics on morphine-induced behavioural effects in mice, Clin. Exp. Pharmacol. Physiol., 41, 255, 10.1111/1440-1681.12203

Patti, 2005, Behavioral characterization of morphine effects on motor activity in mice, Pharmacol. Biochem. Behav., 81, 923, 10.1016/j.pbb.2005.07.004

Broseta, 2000, Lack of specific effects of selective D1 and D2 dopamine antagonists vs. risperidone on morphine-induced hyperactivity, Pharmacol. Biochem. Behav., 66, 189, 10.1016/S0091-3057(00)00207-0

Domino, 1976, Mixed depressant and stimulant actions of morphine and their relationship to brain acetylcholine, Life Sci., 18, 361, 10.1016/0024-3205(76)90213-7

Brady, 1981, Locomotor activity in morphine-dependent and post-dependent rats, Pharmacol. Biochem. Behav., 14, 361, 10.1016/0091-3057(81)90403-2

Tulunay, 1982, The effects of morphine and delta-9-tetrahydrocannabinol on motor activity in rats, Psychopharmacology, 78, 358, 10.1007/BF00433741

Murphy, 2008, A comparison of morphine-induced locomotor activity and mesolimbic dopamine release in C57BL6, 129Sv and DBA2 mice, J. Neurochem., 79, 626, 10.1046/j.1471-4159.2001.00599.x

Christie, 1971, Turning behaviour as an index of the action of amphetamines and ephedrines on central dopamine-containing neurones, Br. J. Pharmacol., 43, 658, 10.1111/j.1476-5381.1971.tb07195.x

Barber, 1973, An automatic apparatus for recording rotational behaviour in rats with brain lesions, Physiol. Behav., 11, 117, 10.1016/0031-9384(73)90134-0

Urs, 2010, A Dopamine D1 receptor-dependent β-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice, Neuropsychopharmacology, 36, 551, 10.1038/npp.2010.186

Ryczko, 2017, Dopamine and the brainstem locomotor networks: From lamprey to human, Front. Neurosci., 11, 295, 10.3389/fnins.2017.00295

Chastain, 2014, Striatal dopamine receptor plasticity in neurotensin deficient mice, Behav. Brain Res., 280, 160, 10.1016/j.bbr.2014.11.014

Borgkvist, 2007, Activation of the cAMP/PKA/DARPP-32 signaling pathway is required for morphine psychomotor stimulation but not for morphine reward, Neuropsychopharmacology, 32, 1995, 10.1038/sj.npp.1301321

Mishra, 2018, Physiological and functional basis of dopamine receptors and their role in neurogenesis: Possible implication for Parkinson’s disease, J. Exp. Neurosci., 12, 1179069518779829, 10.1177/1179069518779829

Horsfall, 2016, The pharmacology and toxicology of the ‘Holy Trinity’, Basic Clin. Pharmacol. Toxicol., 120, 115, 10.1111/bcpt.12655

Torregrossa, M. (2019). Chapter 4-Neural circuit plasticity in addiction. Neural Mechanisms of Addiction, Academic Press.

Oliva, 2016, Ventral tegmental area afferents and drug-dependent behaviors, Front. Psychiatry, 7, 30, 10.3389/fpsyt.2016.00030

Adinoff, 2004, Neurobiologic processes in drug reward and addiction, Harv. Rev. Psychiatry, 12, 305, 10.1080/10673220490910844

Gardner, 2000, Heterogeneity of the mesotelencephalic dopamine fibers: Physiology and pharmacology, Neurosci. Biobehav. Rev., 24, 115, 10.1016/S0149-7634(99)00048-2

Lever, 2006, Rearing on hind legs, environmental novelty, and the hippocampal formation, Rev. Neurosci., 17, 111, 10.1515/REVNEURO.2006.17.1-2.111

Levin, E.D., and Buccafusco, J.J. (2006). Frontiers in neuroscience assessments of cognitive deficits in mutant mice. Animal Models of Cognitive Impairment, CRC Press/Taylor & Francis, Taylor & Francis Group, LLC.

Alves, 2012, High-and Low-Rearing rats differ in the brain excitability controlled by the allosteric benzodiazepine site in the GABAA receptor, J. Behav. Brain Sci., 2, 315, 10.4236/jbbs.2012.23036

Valverde, 2004, Modulation of anxiety-like behavior and morphine dependence in CREB-deficient mice, Neuropsychopharmacology, 29, 1122, 10.1038/sj.npp.1300416

Contet, 2008, Morphine-induced analgesic tolerance, locomotor sensitization and physical dependence do not require modification of mu opioid receptor, cdk5 and adenylate cyclase activity, Neuropsychopharmacology, 54, 475

Zan, 2015, Antagonism of κ opioid receptor in the nucleus accumbens prevents the depressive-like behaviors following prolonged morphine abstinence, Behav. Brain Res., 291, 334, 10.1016/j.bbr.2015.05.053

Aceves, 2017, Nor-binaltorphimine blocks the adverse effects of morphine after spinal cord injury, J. Neurotrauma, 34, 1164, 10.1089/neu.2016.4601

Walsh, 1976, The open-field test: A critical review, Psychol. Bull., 83, 482, 10.1037/0033-2909.83.3.482

Paul, 2018, Age-dependent antinociception and behavioral inhibition by morphine, Pharmacol. Biochem. Behav., 168, 8, 10.1016/j.pbb.2018.03.003

Paul, 2018, Data on prolonged morphine-induced antinociception and behavioral inhibition in older rats, Data Brief., 19, 183, 10.1016/j.dib.2018.05.001

Dominguez, 2013, Prophylaxis and treatment of the side-effects of neuraxial morphine analgesia following cesarean delivery, Curr. Opin. Anaesthesiol., 26, 288, 10.1097/ACO.0b013e328360b086

Raffaeli, 2006, Opioid-related side-effects after intrathecal morphine, Eur. J. Anaesthesiol., 23, 605, 10.1017/S026502150600038X

Benyamin, 2008, Opioid complications and side effects, Pain Physician, 11, S105, 10.36076/ppj.2008/11/S105

Miyamoto, 2011, Why does morphine make you itch?, Cell, 147, 261, 10.1016/j.cell.2011.09.026

Liu, 2011, Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids, Cell, 147, 447, 10.1016/j.cell.2011.08.043

Abe, 2015, Withdrawal of repeated morphine enhances histamine-induced scratching responses in mice, Drug Chem. Toxicol., 38, 167, 10.3109/01480545.2014.922095

Roeckel, 2016, Opioid-induced hyperalgesia: Cellular and molecular mechanisms, Neuroscience, 338, 160, 10.1016/j.neuroscience.2016.06.029

Swartjes, 2012, Morphine induces hyperalgesia without involvement of µ-Opioid receptor or morphine-3-glucuronide, Mol. Med., 18, 1320, 10.2119/molmed.2012.00244

Song, L., Wu, C., and Zuo, Y. (2015). Melatonin prevents morphine-induced hyperalgesia and tolerance in rats: Role of protein kinase C and N-methyl-D-aspartate receptors. BMC Anesthesiol., 15.

Elhabazi, 2014, Assessment of morphine-induced hyperalgesia and analgesic tolerance in mice using thermal and mechanical nociceptive modalities, J. Vis. Exp., 89, e51264

Whistler, 2010, Opioid-receptor-heteromer-specific trafficking and pharmacology, Curr. Opin. Pharmacol., 10, 73, 10.1016/j.coph.2009.09.007

Walwyn, 2009, δ Receptors are required for full inhibitory coupling of μ receptors to voltage-dependent Ca2+ channels in dorsal root ganglion neurons, Mol. Pharmacol., 76, 134, 10.1124/mol.109.055913

Gomes, 2009, Modulation of opioid receptor function by protein-protein interactions, Front. Biosci., 14, 3594

Ballet, 2008, Multiple ligands in opioid research, Protein Pept. Lett., 15, 668, 10.2174/092986608785133672

Lezoualc, 2008, Bivalent ligands as specific pharmacological tools for G protein-coupled receptor dimers, Curr. Drug Discov. Technol., 5, 312, 10.2174/157016308786733591

Yamada, 2006, Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors, Brain Res., 1083, 61, 10.1016/j.brainres.2006.01.095

Sutak, 2007, Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of μ- and δ -opioid receptor antagonists, Br. J. Pharmacol., 151, 877, 10.1038/sj.bjp.0707277

McNaull, 2007, Inhibition of tolerance to spinal morphine antinociception by low doses of opioid receptor antagonists, Eur. J. Pharmacol., 560, 132, 10.1016/j.ejphar.2006.12.013

Dietis, 2009, Simultaneous targeting of multiple opioid receptors: A strategy to improve side-effect profile, Br. J. Anaesth., 103, 38, 10.1093/bja/aep129

Morphy, 2005, Designed multiple ligands. An emerging drug discovery paradigm, J. Med. Chem., 48, 6523, 10.1021/jm058225d

Schiller, 2010, Bi- or multifunctional opioid peptide drugs, Life Sci., 86, 598, 10.1016/j.lfs.2009.02.025

Toll, 2009, Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/μ-opioid receptor ligands: Implications for therapeutic applications, J. Pharmacol. Exp. Ther., 331, 954, 10.1124/jpet.109.157446

Turnaturi, 2016, Multitarget opioid ligands in pain relief: New players in an old game, Eur. J. Med. Chem., 108, 211, 10.1016/j.ejmech.2015.11.028

Anand, 2018, Multifunctional opioid ligands, Gastrointest. Regul. Pept., 247, 21

Cunningham, 2019, Bifunctional opioid receptor ligands as novel analgesics, Neuropharmacology, 151, 195, 10.1016/j.neuropharm.2019.03.006

Agnes, 2008, Structure–activity relationships of bifunctional cyclic disulfide peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors, Peptides, 29, 1413, 10.1016/j.peptides.2008.03.022

Kulkarni, V.V., Lee, Y.S., Salibay, C., Davis, P., Ma, S.-W., Porreca, F., and Hruby, V.J. (2009). Novel analogues of bifunctional ligands for opioid and melanocortin 4 receptor. Peptides for Youth, Springer.

Yamamoto, 2010, Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines, J. Med. Chem., 53, 5491, 10.1021/jm100157m

Yekkirala, 2013, An immunocytochemical-derived correlate for evaluating the bridging of heteromeric mu-delta opioid protomers by bivalent ligands, ACS Chem. Biol., 8, 1412, 10.1021/cb400113d

Guillemyn, 2018, A bifunctional-biased mu-opioid agonist–neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects, Pain, 159, 1705, 10.1097/j.pain.0000000000001262

Tzschentke, 2019, Cebranopadol: A novel first-in-class potent analgesic acting via NOP and opioid receptors, Antisense Res. Appl., 254, 367

Fujita, 2014, Heteromers of μ-δ opioid receptors: New pharmacology and novel therapeutic possibilities, Br. J. Pharmacol., 172, 375, 10.1111/bph.12663

Gomes, 2000, Heterodimerization of mu and delta opioid receptors: A role in opiate synergy, J. Neurosci., 20, RC110, 10.1523/JNEUROSCI.20-22-j0007.2000

Fujita, 2014, Revolution in GPCR signalling: Opioid receptor heteromers as novel therapeutic targets: IUPHAR Review 10, Br. J. Pharmacol., 171, 4155, 10.1111/bph.12798

Gomes, 2013, Identification of a-opioid receptor heteromer-biased agonist with antinociceptive activity, Proc. Natl. Acad. Sci. USA, 110, 12072, 10.1073/pnas.1222044110

Milan-Lobo, L., Enquist, J., Van Rijn, R.M., and Whistler, J.L. (2013). Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism. PLoS ONE, 8.

Wallace, 2008, Phase II, Open-label, multicenter study of combined intrathecal morphine and ziconotide: Addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain, Pain Med., 9, 271, 10.1111/j.1526-4637.2007.00355.x

Krames, E.S., Peckham, P.H., and Rezai, A.R. (2009). Chapter 35-Intrathecal non-opioid analgesics for the control of pain. Neuromodulation, Academic Press.